LEADS BIOLABS-B Shares Surge Over 15% as Key Drug Candidate LBL-024 Enters Priority Review

Deep News07-14

Shares of LEADS BIOLABS-B (09887) surged more than 15% during the morning trading session.

As of the latest update, the stock is up 6.39%, trading at HK$63.30 with a turnover of HK$167 million.

The company announced that six of its latest research findings have been selected for presentation at the 2026 European Society for Medical Oncology Annual Meeting.

Among the six selected studies, two have been chosen for the highest-level oral presentations, while four will be presented as posters, covering treatment areas such as extrapulmonary neuroendocrine carcinoma, biliary tract cancer, and relapsed/refractory multiple myeloma.

Furthermore, the company has been granted a Late-Breaking Abstract status and will submit the full LBA by September 2026.

The company had previously announced that LBL-024 for first-line non-small cell lung cancer was selected for an oral presentation at the World Conference on Lung Cancer this September.

On July 10, the company announced that the Biologics License Application for its self-developed PD-L1/4-1BB bispecific antibody, LBL-024, as a monotherapy for advanced, previously treated extrapulmonary neuroendocrine carcinoma, was approved by China's National Medical Products Administration Center for Drug Evaluation to be included in the priority review and approval process.

The company stated that this milestone signifies the formal locking in of the commercialization timeline for LBL-024, with a clear and anticipated timeline for market approval.

Concurrently, the company is actively advancing various pre-commercialization preparatory work.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156225075?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 11:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156225075","market":"nz","top_or_hot":-1,"title":"LEADS BIOLABS-B Shares Surge Over 15% as Key Drug Candidate LBL-024 Enters Priority Review","media":"Deep News","content":"<p>Shares of <b>LEADS BIOLABS-B</b> (<b>09887</b>) surged more than 15% during the morning trading session.<br><br>As of the latest update, the stock is up 6.39%, trading at HK$63.30 with a turnover of HK$167 million.<br><br>The company announced that six of its latest research findings have been selected for presentation at the 2026 European Society for Medical Oncology Annual Meeting.<br><br>Among the six selected studies, two have been chosen for the highest-level oral presentations, while four will be presented as posters, covering treatment areas such as extrapulmonary neuroendocrine carcinoma, biliary tract cancer, and relapsed/refractory multiple myeloma.<br><br>Furthermore, the company has been granted a Late-Breaking Abstract status and will submit the full LBA by September 2026.<br><br>The company had previously announced that LBL-024 for first-line non-small cell lung cancer was selected for an oral presentation at the World Conference on Lung Cancer this September.<br><br>On July 10, the company announced that the Biologics License Application for its self-developed PD-L1/4-1BB bispecific antibody, LBL-024, as a monotherapy for advanced, previously treated extrapulmonary neuroendocrine carcinoma, was approved by China's National Medical Products Administration Center for Drug Evaluation to be included in the priority review and approval process.<br><br>The company stated that this milestone signifies the formal locking in of the commercialization timeline for LBL-024, with a clear and anticipated timeline for market approval.<br><br>Concurrently, the company is actively advancing various pre-commercialization preparatory work.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEADS BIOLABS-B Shares Surge Over 15% as Key Drug Candidate LBL-024 Enters Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEADS BIOLABS-B Shares Surge Over 15% as Key Drug Candidate LBL-024 Enters Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-07-14 11:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>LEADS BIOLABS-B</b> (<b>09887</b>) surged more than 15% during the morning trading session.<br><br>As of the latest update, the stock is up 6.39%, trading at HK$63.30 with a turnover of HK$167 million.<br><br>The company announced that six of its latest research findings have been selected for presentation at the 2026 European Society for Medical Oncology Annual Meeting.<br><br>Among the six selected studies, two have been chosen for the highest-level oral presentations, while four will be presented as posters, covering treatment areas such as extrapulmonary neuroendocrine carcinoma, biliary tract cancer, and relapsed/refractory multiple myeloma.<br><br>Furthermore, the company has been granted a Late-Breaking Abstract status and will submit the full LBA by September 2026.<br><br>The company had previously announced that LBL-024 for first-line non-small cell lung cancer was selected for an oral presentation at the World Conference on Lung Cancer this September.<br><br>On July 10, the company announced that the Biologics License Application for its self-developed PD-L1/4-1BB bispecific antibody, LBL-024, as a monotherapy for advanced, previously treated extrapulmonary neuroendocrine carcinoma, was approved by China's National Medical Products Administration Center for Drug Evaluation to be included in the priority review and approval process.<br><br>The company stated that this milestone signifies the formal locking in of the commercialization timeline for LBL-024, with a clear and anticipated timeline for market approval.<br><br>Concurrently, the company is actively advancing various pre-commercialization preparatory work.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000252152.HKD","symbol_name":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","start_time":0,"source_url":"","article_id":"1156225075","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156225075","pubTimestamp":1784001137,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shares of LEADS BIOLABS-B (09887) surged more than 15% during the morning trading session.As of the latest update, the stock is up 6.39%, trading at HK$63.30 with a turnover of HK$167 million.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","BK1161":"生物科技","09887":"维立志博-B","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元"},"translate_title":"随着关键候选药物 LBL-024 进入优先审查，LEADS BIOLABS-B 股价飙升超过 15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"Shares of LEADS BIOLABS-B (09887) surged more than 15% during the morning trading session.As of the latest update, the stock is up 6.39%, trading at HK$63.30 with a turnover of HK$167 million.The company announced that six of its latest research findings have been selected for presentation at the 2026 European Society for Medical Oncology Annual Meeting.Among the six selected studies, two have been chosen for the highest-level oral presentations, while four will be presented as posters, covering treatment areas such as extrapulmonary neuroendocrine carcinoma, biliary tract cancer, and relapsed/refractory multiple myeloma.Furthermore, the company has been granted a Late-Breaking Abstract status and will submit the full LBA by September 2026.The company had previously announced that LBL-024 for first-line non-small cell lung cancer was selected for an oral presentation at the World Conference on Lung Cancer this September.On July 10, the company announced that the Biologics License Application for its self-developed PD-L1/4-1BB bispecific antibody, LBL-024, as a monotherapy for advanced, previously treated extrapulmonary neuroendocrine carcinoma, was approved by China's National Medical Products Administration Center for Drug Evaluation to be included in the priority review and approval process.The company stated that this milestone signifies the formal locking in of the commercialization timeline for LBL-024, with a clear and anticipated timeline for market approval.Concurrently, the company is actively advancing various pre-commercialization preparatory work.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156225075","isCrawlerRequest":true}